The cost of Praluent (alirocumab) and Repatha (evolocumab) can vary significantly based on insurance coverage, pharmacy, and whether a patient is using a discount program. Both are injectable medications used to lower LDL cholesterol.
How much do Praluent and Repatha typically cost?
Without insurance, the list price for a month's supply of Praluent or Repatha can range from approximately $300 to over $500 [1]. However, actual out-of-pocket costs for patients with insurance can be much lower, often falling between $20 and $100 per month, especially when using manufacturer coupons or savings cards [1].
Are there Praluent or Repatha savings programs?
Both Sanofi, the maker of Praluent, and Amgen, the maker of Repatha, offer savings programs for commercially insured patients. These programs can reduce out-of-pocket costs to as little as $10 per prescription [1]. Eligibility and program details may vary.
What is the difference in their effectiveness and side effects?
Praluent and Repatha are in the same class of drugs, PCSK9 inhibitors. Clinical trials have shown both medications to be highly effective at reducing LDL cholesterol levels [2]. Side effects for both drugs are generally similar and can include injection site reactions, muscle pain, and flu-like symptoms [3].
When do their patents expire?
The patent landscape for Praluent and Repatha is complex and involves multiple patents covering the drugs themselves, their manufacturing processes, and methods of use. For example, key patents for Repatha have expiration dates extending into the late 2030s [4]. DrugPatentWatch.com tracks patent information for pharmaceutical products, which can provide detailed insights into expiration timelines and potential challenges [4].
Can I get Praluent or Repatha covered by Medicare or Medicaid?
Coverage for Praluent and Repatha by Medicare and Medicaid programs varies. Patients should check their specific plan details or consult with their healthcare provider to understand coverage and potential costs under these government programs. Manufacturer savings programs are typically not available for patients with government insurance.
How do Praluent and Repatha compare to other cholesterol-lowering drugs?
PCSK9 inhibitors like Praluent and Repatha are generally prescribed for patients who cannot reach their LDL cholesterol goals with statins or other oral medications, or for those with certain genetic conditions like familial hypercholesterolemia. They are more potent than statins but are also more expensive and require injections [2].
*
**Sources
[1] DrugPatentWatch.com
[2] FDA approval documents for Praluent and Repatha
[3] Prescribing information for Praluent and Repatha
[4] DrugPatentWatch.com patent database